TSI boosts patent portfolio on ATP
acquired exclusive rights to an extensive portfolio of patents for
delivery of Adenosine 5'-Triphosphate (ATP). The deal could see
ATP's launch on the market as a new performance-enhancing
ingredient.
Nutraceuticals firm Technical Sourcing said today that it has acquired exclusive rights to an extensive portfolio of patents for delivery of Adenosine 5'-Triphosphate (ATP). The deal could see ATP's launch on the market as a new performance-enhancing ingredient.
TSI has gained rights to six issued patents and four pending patent applications from Dr Eliezer Rapaport, an expert in adenosine nucleotides, who is credited with the discovery that organ, red blood cell, and blood plasma pools of ATP can be expanded by systemic administration of ATP.
The patents include the use of adenine nucleotides for raising liver and blood plasma ATP concentrations and anticancer activities caused by increasing blood and plasma ATP.
The patents will support TSI's own domestic and foreign patent-pending ATP technology, which delivers ATP for reducing muscle fatigue and enhancing human performance.
Larry Kolb, TSI's president and co-founder, said: "This deal provides for the first legitimate entry of ATP into the marketplace." He described ATP as "the 'best in class' performance-enhancing ingredient".
TSI markets a wide range of botanicals, such as green tea extract and ginseng, as well as nutraceutical ingredients, and consumer brands such as the amino acid complex Promilin.
The company will conduct a seminar on the latest muscle glycogen resynthesis research carried out on the patent-pending Promilin at SupplySide West in Las Vegas, on October 2 at the Venetian Hotel/Sands Expo, Room 801/802.
